Moderna's AI-Designed mRNA Cancer Therapy Succeeds in Phase 3 with Keytruda
timshi_ai · x · 2026-08-20
Moderna announced its individualized cancer therapy combined with Keytruda succeeded in a Phase 3 trial, showing mRNA's potential beyond vaccines.
VC firm KernaLabs says it bet three years ago, as LLMs rapidly progressed, that AI models could outperform human-led design to create better mRNAs — a direction now clinically validated. Musk previously commented that artificial RNA essentially makes curing diseases a software problem.
More from Research
- Dev critiques compiling fast programs into slow neural nets: fun, but not useful — ctjlewis · 2026-10-16
- New paper uses revealed-preference methods to unpack why AI agents cooperate — brwilder · 2026-10-16
- Logit lens on a Beat Saber finetune reveals it reuses language grammar circuits — ctjlewis · 2026-10-16
- 128×128 record stands: how intermediate-work experiments foreshadowed reasoning models — ctjlewis · 2026-10-16
- TeamFusion: preference-based AI proxies debate to preserve minority views in team decisions — burkov · 2026-10-16
- MIT's C-GMT gives humanoid robots whole-body compliance without sacrificing motion tracking — MIT_CSAIL · 2026-10-16